Gale St Clare Smith

US Patent:

7598075, Oct 6, 2009

Filed:

Apr 1, 2005

Appl. No.:

11/097994

Inventors:

Gale E. Smith - Darnestown MD, US
John Knell - Rockville MD, US
Andrei I. Voznesensky - West Hartford CT, US

Assignee:

Protein Sciences Corporation - Meriden CT

International Classification:

C12M 1/12

US Classification:

4352972

Abstract:

Disclosed and claimed is apparatus and methods for the growth of cells to high density, products therefrom and uses thereof. Also disclosed and claimed is the use of this method for the growth to high-density insect cells, such as the Sf900+ cell line (ATCC: CRL 12579). Further disclosed is the infection of Sf900+ cells at high cell density with wild type and recombinant baculoviruses to produce baculovirus and DNA or gene or expression products.

US Patent:

7879601, Feb 1, 2011

Filed:

Oct 5, 2009

Appl. No.:

12/573468

Inventors:

Gale E. Smith - Darnestown MD, US
John Knell - Rockville MD, US
Andrei I. Voznesensky - West Hartford CT, US

Assignee:

Protein Sciences Corporation - Meriden CT

International Classification:

C12M 1/12

US Classification:

4352972

Abstract:

Disclosed and claimed is apparatus and methods for the growth of cells to high density, products therefrom and uses thereof. Also disclosed and claimed is the use of this method for the growth to high-density insect cells, such as the Sf900+ cell line (ATCC: CRL 12579). Further disclosed is the infection of Sf900+ cells at high cell density with wild type and recombinant baculoviruses to produce baculovirus and DNA or gene or expression products.

US Patent:

8080255, Dec 20, 2011

Filed:

Oct 18, 2006

Appl. No.:

11/582540

Inventors:

Gale Smith - Rockville MD, US
Rick Bright - Rockville MD, US
Peter Pushko - Rockville MD, US
Jinyou Zhang - Rockville MD, US
Kutub Mahmood - Rockville MD, US

Assignee:

Novavax Inc. - Rockville MD

International Classification:

A61K 39/145

US Classification:

4242101, 4242091, 4242051, 4242061

Abstract:

The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

US Patent:

8506967, Aug 13, 2013

Filed:

Dec 19, 2008

Appl. No.:

12/340186

Inventors:

Gale Smith - Rockville MD, US
Rick Bright - Washington DC, US
Peter M. Pushko - Rockville MD, US
Jinyou Zhang - Plainsboro NJ, US
Kutub Mahmood - Cupertino CA, US

Assignee:

Novavax, Inc. - Rockville MD

International Classification:

A61K 39/145

US Classification:

4242101, 4242091, 4242061, 4242051

Abstract:

The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

US Patent:

8551756, Oct 8, 2013

Filed:

Jan 19, 2010

Appl. No.:

12/689826

Inventors:

Gale Smith - Rockville MD, US
Peter Pushko - Frederick MD, US

Assignee:

Novavax, Inc. - Rockville MD

International Classification:

C12N 7/00
C12N 7/04

US Classification:

4352351, 435 691, 435236, 435239

Abstract:

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

US Patent:

20070244043, Oct 18, 2007

Filed:

Mar 7, 2006

Appl. No.:

11/369788

Inventors:

Gale Smith - Darnestown MD, US
Peter Pushko - Frederick MD, US
Vittoria Cioce - Kensington MD, US

International Classification:

A61K 48/00
C07H 21/04
C07K 14/00
C12N 1/21
C12N 5/06
C12N 7/01
C12P 1/04

US Classification:

514012000, 435235100, 435252300, 435320100, 435325000, 435069100, 530350000, 536023500

Abstract:

The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.

US Patent:

20080233150, Sep 25, 2008

Filed:

Nov 16, 2007

Appl. No.:

11/941768

Inventors:

Gale SMITH - Rockville MD, US
Peter Pushko - Rockville MD, US
Mike Massare - Rockville MD, US
Yingyun Wu - Rockville MD, US
Kutub Mahmood - Rockville MD, US

International Classification:

A61K 39/155
A61P 31/12
C07K 16/00

US Classification:

4242111, 5303873

Abstract:

The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV.

US Patent:

20090017066, Jan 15, 2009

Filed:

May 27, 2008

Appl. No.:

12/127625

Inventors:

Gale Smith - Rockville MD, US
Peter Pushko - Rockville MD, US
Kutub Mahmood - Rockville MD, US
Bin Zhao - Rockville MD, US

International Classification:

A61K 39/145
C07K 14/11
A61P 31/16
C12P 21/02

US Classification:

4242091, 530324, 435 691

Abstract:

The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza.